A Two-stage Theory of Carcinogenesis in Relation to the Age Distribution of Human Cancer

P. Armitage, Ronald J. Doll

British Journal of Cancer

Two-stage TheoryMalignant DiseaseMedicineEpidemiology Of CancerCancer Growth +9

Dinaciclib (SCH 727965), a Novel and Potent Cyclin-Dependent Kinase Inhibitor

David Parry, Timothy J. Guzi, Nicole R. Davis, +14

Molecular Cancer Therapeutics

PharmacotherapyCancer BiologyTumor BiologyCdk9 ActivityReceptor Tyrosine Kinase +14

Antitumor activity of SCH 66336, an orally bioavailable tricyclic inhibitor of farnesyl protein transferase, in human tumor xenograft models and wap-ras transgenic mice.

Ming Liu, Matthew Bryant, Jianping Chen, +21

PubMed

Sch 66336Chemoprevention StrategyFarnesyl Protein TransferaseOncogenic AgentMedicine +13

Discovery of Dinaciclib (SCH 727965): A Potent and Selective Inhibitor of Cyclin-Dependent Kinases

Kamil Paruch, Michael P. Dwyer, Carmen Álvarez, +29

ACS Medicinal Chemistry Letters

Drug TargetPathologyChemical BiologyPharmaceutical ChemistryTumor Biology +19

Novel Tricyclic Inhibitors of Farnesyl Protein Transferase

W. Robert Bishop, Richard Bond, Joanne Petrin, +12

Journal of Biological Chemistry

Structural interaction of natural and synthetic inhibitors with the venom metalloproteinase, atrolysin C (form d).

Daizhou Zhang, Istvan Botos, F. Xavier Gomis‐Rüth, +6

Proceedings of the National Academy of Sciences

Selective halogenation of steroids using attached aryl iodide templates

Ronald Breslow, Richard J. Corcoran, Barry B. Snider, +3

Journal of the American Chemical Society

HalogenationPharmaceutical ScienceMolecular SciencesEngineeringBiochemistry +11

Ras oncoprotein inhibitors: The discovery of potent, ras nucleotide exchange inhibitors and the structural determination of a drug-protein complex

Arthur G. Taveras, Stacy Remiszewski, Ronald J. Doll, +32

Bioorganic & Medicinal Chemistry

Molecular DockingDrug TargetBiochemistryDrug-protein ComplexMedicine +8

The Farnesyl Transferase Inhibitor SCH 66336 Induces a G2 → M or G1 Pause in Sensitive Human Tumor Cell Lines

Hena R. Ashar, Linda James, Kimberly Gray, +9

Experimental Cell Research

Tumor BiologyG1 PauseOncogenic AgentMedicineCell Biology +6

SCH529074, a Small Molecule Activator of Mutant p53, Which Binds p53 DNA Binding Domain (DBD), Restores Growth-suppressive Function to Mutant p53 and Interrupts HDM2-mediated Ubiquitination of Wild Type p53

Mark J. Demma, Eugene Maxwell, Robert Ramos, +10

Journal of Biological Chemistry